Niacin, in its various forms, appears to offer several real benefits for kidney health, but the picture is far from simple. Population data suggest that higher dietary niacin intake is linked to lower rates of chronic kidney disease and lower mortality among people who already have it. At the same time, high-dose supplemental niacin carries side effects that matter more when kidneys are compromised, and a 2024 discovery about one of niacin’s breakdown products has raised new questions about cardiovascular safety. Whether niacin helps or harms your kidneys depends on the form you take, how much, and how well your kidneys are working to begin with.
What Population Studies Say About Dietary Niacin and Kidney Health
Before getting into supplements and clinical trials, it is worth looking at what happens in people who simply eat more niacin-rich foods. A cross-sectional study using over a decade of U.S. national health survey data found a clear non-linear relationship between niacin intake and chronic kidney disease in men. People in the highest intake group had roughly 25% lower odds of having CKD compared to those eating the least niacin, with an inflection point around 27 mg per day, after which additional intake did not keep adding benefit.1PubMed Central. Association between niacin intake and chronic kidney disease in male participants-a cross-sectional study from the NHANES (2005-2018) That inflection point is only slightly above the recommended daily allowance for adults, which sits at 14 to 16 mg.
A separate study looked at the other end of the disease spectrum: people who already had CKD. Among those patients, higher dietary niacin intake was associated with lower all-cause mortality. Compared to CKD patients eating 19 mg or less per day, those consuming more than 33 mg had about a 21% lower risk of dying during the follow-up period.2PubMed Central. Association of dietary niacin intake with all-cause mortality in chronic kidney disease: A retrospective cohort study of NHANES These are observational findings, so they cannot prove that niacin itself caused the benefit. People who eat more niacin also tend to eat more protein-rich whole foods, which could be a confounding factor. Still, the consistency of the association across two large datasets is notable and suggests that getting enough niacin from food is, at minimum, not harmful to kidneys and may be protective.
Phosphate Control in Kidney Disease
The most thoroughly studied kidney-specific use of niacin involves phosphate management. When kidneys lose function, they become less able to excrete phosphorus, and the resulting buildup drives a cascade of problems: calcium gets pulled from bones, blood vessels calcify, and parathyroid hormone levels climb. Controlling phosphate is one of the central challenges in managing advanced kidney disease, and traditional phosphate binders (pills taken with meals to grab phosphorus in the gut) are the standard approach. Niacin and its amide form, nicotinamide, attack the problem from a different angle: they reduce the amount of phosphorus the intestines absorb in the first place by blocking a specific transporter protein in the gut wall.3PubMed Central. Use of nicotinamide to treat hyperphosphatemia in dialysis patients
This mechanism was first shown in rat models of kidney failure, where nicotinamide lowered phosphorus absorption and appeared to slow the deterioration of kidney function itself.4PubMed. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure In humans, a randomized controlled trial of hemodialysis patients found that niacin significantly lowered phosphate levels by the third month of treatment and continued to push them down through six months. Parathyroid hormone levels also dropped substantially in the niacin group, falling to roughly half the levels seen in the control group by month six.5The Egyptian Journal of Internal Medicine. The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial This dual effect on both phosphate and parathyroid hormone makes niacin particularly attractive, because most phosphate binders only address the phosphate side of the equation.
Lipid Benefits in Kidney Patients
People with chronic kidney disease almost universally have abnormal cholesterol and triglyceride profiles, and these lipid problems contribute to the very high cardiovascular death rate in this population. Niacin has long been recognized as one of the most effective agents for raising HDL cholesterol and lowering triglycerides, and those effects hold up in kidney patients. A study of CKD patients taking low-dose niacin found significant increases in HDL and decreases in triglycerides over 24 weeks.6PubMed Central. Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease What makes this especially interesting for kidney disease is that niacin can simultaneously improve lipids and lower phosphate, tackling two major problems with one agent.7PubMed. Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials
A recent trial in hemodialysis patients also found that niacin kept uric acid levels stable over three months, while the control group saw a nearly 28% spike in uric acid.8Frontiers in Medicine. Targeting cardiovascular and metabolic risk modification in end stage renal disease (ESRD): a randomized controlled clinical trial on niacin’s effects on lipoprotein(a) and biochemical markers in hemodialysis patients Rising uric acid is a common and troublesome complication in dialysis patients, so this stabilizing effect is a meaningful secondary benefit.
Vascular Calcification
One of the deadliest complications of kidney disease is the progressive hardening of blood vessel walls. As phosphate and calcium go haywire, calcium deposits accumulate in arteries, making them stiff and prone to cardiovascular events. Recent animal research has shown that niacin can directly inhibit this vascular calcification process, working through a pathway involving proteins called SIRT1 and SIRT6 that help maintain healthy blood vessel cell behavior. In mice with CKD-induced calcification, niacin treatment reduced the severity of calcium deposits in the vasculature.9Cell Death Discovery. Niacin inhibits vascular calcification via modulating of SIRT1/SIRT6 signaling pathway This finding links niacin’s phosphate-lowering effect to a more direct protective action on the blood vessel wall itself, suggesting the benefit goes beyond just fixing a lab number.
NAD+ Precursors and Acute Kidney Injury
A separate line of research focuses not on chronic kidney disease but on acute kidney injury, the sudden loss of kidney function that can occur after surgery, contrast dye exposure, or toxic drug exposure. The underlying idea is that niacin and its relatives (nicotinamide, NMN) serve as raw materials for making NAD+, a molecule that cells need for energy production and stress repair. Kidney cells have high energy demands and are vulnerable when NAD+ levels drop, which happens with aging and during acute stress.
In mice, supplementation with NMN restored NAD+ levels in aging kidneys and protected both young and old animals against cisplatin-induced acute kidney injury. The protection appeared to work through a pathway involving a protein called SIRT1, which acts as a cellular stress sensor.10PubMed Central. Nicotinamide Mononucleotide, an NAD+ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner In other mouse experiments, nicotinamide given before or after blood-flow restriction to the kidneys improved kidney function markers. Pre-treatment with nicotinamide also protected against cisplatin-induced kidney damage.11Clinical Kidney Journal. Nicotinamide and acute kidney injury
These results are promising but carry an important caveat: they are almost entirely from animal studies. The doses used in mice do not translate directly to human doses, and what protects a mouse kidney may not work the same way in a person. No large human trials have yet confirmed that taking niacin or NMN before surgery or contrast dye exposure prevents acute kidney injury. Researchers are interested, but the clinical evidence has not caught up to the animal data.
Protection in Diabetic Kidney Disease
Diabetic kidney disease is the leading cause of kidney failure worldwide, and several animal studies suggest niacin-related compounds could help slow its progression. In diabetic mice, short-term NMN treatment reduced the spillage of protein into urine, limited the structural damage to filtering units in the kidney, and improved markers of kidney cell health. These benefits persisted for weeks after the treatment period ended, suggesting the cells retained a kind of metabolic memory from the NAD+ boost.12PubMed Central. Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy A more recent study found that NMN protected the delicate cells (podocytes) that form the kidney’s filtration barrier by suppressing inflammation and preserving their structural integrity.13PubMed Central. Nicotinamide mononucleotide protects against diabetic nephropathy via IL-6/Rab5-mediated crosstalk between proximal tubular epithelial cells and podocytes
Nicotinamide itself showed similar protective effects in a different type of kidney injury model, reducing protein leakage, scarring, inflammation, and oxidative stress.14PubMed. Nicotinamide ameliorates podocyte injury and albuminuria in adriamycin-induced nephropathy Again, all of this is in animals. The consistency of the findings across different mouse models and different niacin-family compounds strengthens the case, but human trials specifically for diabetic kidney disease are still needed.
The Metabolite Concern
In early 2024, a study published in Nature Medicine introduced a wrinkle that received widespread media attention. When the body processes excess niacin, it produces breakdown products, two of which (known by shorthand as 2PY and 4PY) turned out to be associated with increased risk of major cardiovascular events like heart attack and stroke. In two large patient cohorts, people with higher blood levels of 4PY had roughly double the risk of a cardiovascular event over the following three years. Further experiments showed that 4PY triggered inflammation in blood vessel walls, promoting the kind of immune cell sticking that begins the process of plaque formation.15PubMed Central. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
This finding is concerning for kidney patients specifically because impaired kidneys are less efficient at clearing these metabolites. Pharmacokinetic research on extended-release niacin showed that in dialysis patients, the blood levels and half-life of niacin metabolites are significantly higher than in people with milder kidney impairment, and dialysis itself did not effectively remove them.16Nephrology Dialysis Transplantation. Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients The implication is that kidney patients taking supplemental niacin could accumulate more 4PY than people with normal kidney function, potentially amplifying the cardiovascular risk.
It is worth keeping perspective on this finding. The 2024 study measured metabolite levels, not niacin supplementation directly, and the body produces these metabolites from niacin obtained through any source, including food. People with naturally high 4PY levels may differ from the general population in ways the study could not fully account for. The finding has not yet led to any changes in clinical guidelines, but it has added urgency to the call for better long-term safety data on niacin supplementation, especially at high doses in kidney patients.
Why the Form of Niacin Matters
One of the most confusing aspects of this topic is that “niacin” actually refers to a family of related compounds that behave differently in the body. The two main forms are nicotinic acid (what most people mean by “niacin”) and nicotinamide (sometimes called niacinamide). Both are forms of vitamin B3 and both serve as NAD+ precursors, but their side-effect profiles differ, and the kidney research has used both interchangeably in ways that make generalization tricky.17PubMed Central. Nicotinamide and phosphate homeostasis in chronic kidney disease
Nicotinic acid is the form that causes flushing, the uncomfortable skin reddening and warmth that makes many people stop taking it. It is also the form with the strongest effects on lipids. Nicotinamide does not cause flushing and is the form most studied for phosphate control and kidney protection. However, nicotinamide’s metabolism consumes more of a nutrient called betaine than nicotinic acid does at the same dose, which could matter for people already low in methyl donors.18PubMed. Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels
Then there are the newer NAD+ precursors like NMN and nicotinamide riboside, which are the forms used in much of the animal research on acute kidney injury and diabetic kidney disease. These are sold as supplements but have far less human safety data, and their metabolism and metabolite profiles in kidney patients are not well characterized. If you are considering any of these compounds for kidney-related reasons, the specific form and dose are not interchangeable details.
Side Effects That Matter More With Impaired Kidneys
Beyond the metabolite concern, niacin and nicotinamide have several side effects that are amplified or more consequential in kidney patients. A double-blind trial in hemodialysis patients found that nicotinamide caused a significant drop in platelet counts by weeks four and eight compared to baseline.19PubMed. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial For dialysis patients who already require blood-thinning medications during their treatments, lower platelet counts increase bleeding risk. This side effect was dose-dependent and reversed when the supplement was stopped, but it means platelet monitoring is necessary during treatment.
Other commonly reported side effects across niacin trials in kidney patients include gastrointestinal symptoms like nausea and diarrhea, which can affect nutritional status in a population that already struggles to maintain adequate intake. The flushing caused by nicotinic acid is more of a tolerance problem than a medical one, but it is the primary reason patients drop out of studies and stop taking the drug in practice. Extended-release formulations reduce flushing but, as noted, may lead to higher metabolite accumulation in kidney patients because of their altered clearance.
Niacin and Kidney Transplant Recipients
Kidney transplant recipients represent a unique population. They take immunosuppressive drugs that increase their risk of skin cancer, and nicotinamide has shown cancer-prevention benefits in people with normal immune systems. A large randomized trial tested whether nicotinamide could reduce skin cancers in organ transplant recipients. It did not: at 12 months, the nicotinamide group developed essentially the same number of new skin cancers as the placebo group. On the positive side, the trial found no significant differences in adverse events or changes in blood or urine tests between groups, suggesting nicotinamide at these doses was at least safe in transplant patients even if it was not effective for its intended purpose.20New England Journal of Medicine. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients
NAD+ and Kidney Development
An entirely different angle on niacin and kidneys comes from developmental biology. NAD+ is essential for normal organ formation during pregnancy, including kidney development. Research published in the New England Journal of Medicine identified families in which genetic defects in NAD+ synthesis caused congenital malformations, and showed that supplementing niacin during pregnancy in mice with the same genetic defects prevented those malformations.21PubMed. NAD Deficiency, Congenital Malformations, and Niacin Supplementation A meta-analysis of human studies found that mothers with insufficient niacin intake had a modestly higher likelihood of having babies with congenital abnormalities.22PubMed. Effect of maternal dietary niacin intake on congenital anomalies: a systematic review and meta-analysis While this research is not about adult kidney disease, it underscores just how fundamental niacin is to kidney biology from the very beginning of life. The kidneys, which are among the most metabolically active organs in the body, depend on adequate NAD+ from formation through old age.